Lyell Immunopharma (NASDAQ:LYEL) Posts Quarterly Earnings Results

by · The Cerbat Gem

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52), Zacks reports. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.

Lyell Immunopharma Stock Performance

NASDAQ LYEL traded down $0.02 on Tuesday, hitting $0.67. The stock had a trading volume of 482,506 shares, compared to its average volume of 1,061,552. The firm has a 50-day moving average of $0.63 and a 200-day moving average of $0.94. Lyell Immunopharma has a 52-week low of $0.51 and a 52-week high of $3.15. The company has a market capitalization of $194.49 million, a price-to-earnings ratio of -0.84 and a beta of -0.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Read Our Latest Research Report on Lyell Immunopharma

About Lyell Immunopharma

(Get Free Report)

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

See Also